H.C. Wainwright Remains Bullish on Harmony Biosciences Holdings (HRMY)

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 30, H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) and set a price target of $70.00.

Is Harmony Biosciences Holdings, Inc. (HRMY) the Best Small-Cap Growth Stock to Buy Now?

A close-up of a pharmaceutical drug bottle, showcasing the potential of the company’s innovative therapies.

The company reported strong fiscal Q1 2025 results, with net revenue for WAKIX (pitolisant) in narcolepsy reaching $184.7 million for the quarter, reflecting a 20% year-over-year growth. It projects 2025 net revenue to be in the range of $820 to $860 million.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) also experienced a 19% year-over-year increase in net income, building on four consecutive years of profitability. It increased its cash and investments to more than $600 million on the balance sheet.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company that develops and commercializes therapies to treat neurological disorders. Its product, WAKIX, is a molecule that increases histamine signaling in the brain by binding to H3 receptors. The company has one of the strongest pipelines for people with rare neurological diseases.

While we acknowledge the potential of HRMY to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than XXXX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.